doxylamine succinate and pyridoxine hydrochloride

FDA Drug Profile — DICLEGIS, BONJESTA

doxylamine succinate and pyridoxine hydrochloride is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand names including DICLEGIS, BONJESTA. Available dosage forms: tablet, delayed release, tablet, extended release.

Drug details

Generic Name
doxylamine succinate and pyridoxine hydrochloride
Brand Names
DICLEGIS, BONJESTA
Application Number
NDA021876
Sponsor
Duchesnay USA, Inc.
NDC Codes
2
Dosage Forms
TABLET, DELAYED RELEASE, TABLET, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
DOXYLAMINE SUCCINATE, PYRIDOXINE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets havenot been studied in women with hyperemesis gravidarum. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are a fixed dose combination drug product of doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a Vitamin B 6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.